1. Home
  2. ATNM vs SQNS Comparison

ATNM vs SQNS Comparison

Compare ATNM & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • SQNS
  • Stock Information
  • Founded
  • ATNM 2000
  • SQNS 2003
  • Country
  • ATNM United States
  • SQNS France
  • Employees
  • ATNM N/A
  • SQNS N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • ATNM Health Care
  • SQNS Technology
  • Exchange
  • ATNM Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • ATNM 51.5M
  • SQNS 46.5M
  • IPO Year
  • ATNM N/A
  • SQNS 2011
  • Fundamental
  • Price
  • ATNM $1.54
  • SQNS $1.72
  • Analyst Decision
  • ATNM Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • ATNM 3
  • SQNS 1
  • Target Price
  • ATNM $4.67
  • SQNS $7.50
  • AVG Volume (30 Days)
  • ATNM 229.8K
  • SQNS 87.0K
  • Earning Date
  • ATNM 05-09-2025
  • SQNS 05-06-2025
  • Dividend Yield
  • ATNM N/A
  • SQNS N/A
  • EPS Growth
  • ATNM N/A
  • SQNS N/A
  • EPS
  • ATNM N/A
  • SQNS 2.16
  • Revenue
  • ATNM N/A
  • SQNS $38,858,000.00
  • Revenue This Year
  • ATNM N/A
  • SQNS N/A
  • Revenue Next Year
  • ATNM N/A
  • SQNS $93.87
  • P/E Ratio
  • ATNM N/A
  • SQNS $0.80
  • Revenue Growth
  • ATNM N/A
  • SQNS 40.06
  • 52 Week Low
  • ATNM $1.03
  • SQNS $0.95
  • 52 Week High
  • ATNM $8.64
  • SQNS $4.28
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 49.81
  • SQNS 41.89
  • Support Level
  • ATNM $1.56
  • SQNS $1.77
  • Resistance Level
  • ATNM $1.69
  • SQNS $1.90
  • Average True Range (ATR)
  • ATNM 0.11
  • SQNS 0.09
  • MACD
  • ATNM -0.01
  • SQNS 0.01
  • Stochastic Oscillator
  • ATNM 32.18
  • SQNS 47.06

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: